How Pfizer Scaled Up Manufacturing of Their Breakthrough Vaccine to Help Prevent the Spread of COVID-19

At Pfizer, we worked at an unprecedented speed to execute one of the most successful manufacturing operations and distributions in history to help prevent COVID-19.

Manufacturing Capabilities

Pfizer operates one of the most sophisticated supply chain systems in the industry, with 37 owned sites across 25 countries and more than 300 suppliers globally.

- Globally, we have more than 30,000 colleagues
- Supplying vaccines to 185 countries
- Producing more than 50 billion doses of medications per year
- For biologics, vaccines & sterile injectables, we reach 1.4 billion patients
  Reaching 1 out of every 6 people
An Unprecedented Manufacturing Success

In 2022, Pfizer met its commitment to manufacture more than 4.5 billion doses of the Pfizer-BioNTech COVID-19 Vaccine worldwide.

Pfizer has manufacturing and distribution sites across the world for the COVID-19 vaccine.

Global PGS Map

How It Happened

Pfizer's manufacturing and supply chain professionals took several steps to accelerate the scale-up and manufacturing of the vaccine to ensure it was one of the most successful manufacturing operations in history.

- Upgrading technology to enable rapid facility, equipment and process design planning
- Maintaining two parallel supply chains for appropriate redundancies
- Modifying facilities for the vaccine formulations and re-prioritizing capacity
- Hiring and training staff to give our operations even more support and flexibility
- Investing at risk so we can quickly produce as many doses of vaccine as possible
- Made process improvements to increase production